First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era

Author:

Urso Antonio1,Cavazzini Francesco1,Ballardini Maria Pia1,Gambara Silvia1,Consolo Sara1,Rigolin Gian Matteo1ORCID,Cuneo Antonio1ORCID

Affiliation:

1. Hematology Unit, University of Ferrara, 44121 Ferrara, Italy

Abstract

Bruton tyrosine kinase inhibitors (BTKi) and the BCL2 inhibitor venetoclax, with or without the anti-CD20 monoclonal antibody Obinutuzumab, represent the preferred options for the first-line therapy of CLL because they are more effective and may improve quality of life. However, patient inclusion criteria are heterogeneous across trials designed for older patients, and the identification of CLL-specific parameters identifying unfit patients at risk of developing drug-specific adverse events is required to guide treatment choice. Due to inclusion/exclusion criteria in trials, higher discontinuation rates with BTKi were reported in real-world studies, and registry analyses provided useful information on factors predicting earlier discontinuation in a real-world setting. Though targeted agents were shown to be cost-effective treatments in high-income countries, the out-of-pocket expenses may limit accessibility to these drugs, and the overall expenditure for new drugs in CLL is projected to increase substantially, posing an issue for sustainability. This being said, the choice of a finite-duration treatment based on venetoclax-containing regimens or treatment until progression with BTKi is today possible in high-income countries, and the therapy choice drivers are represented by coexisting medical conditions rather than age, patient expectations, logistics, and sustainability.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference119 articles.

1. National Cancer Institute (2023, May 15). Chronic Lymphocytic Leukemia—Cancer Stat Facts, Available online: https://seer.cancer.gov/statfacts/html/clyl.html.

2. Cancer Statistics, 2023;Siegel;CA A Cancer J. Clin.,2023

3. (2023, May 15). Haematological Malignancy Research Network. Available online: https://hmrn.org/statistics/prevalence.

4. Long-Term Trends in the Loss in Expectation of Life after a Diagnosis of Chronic Lymphocytic Leukemia: A Population-Based Study in the Netherlands, 1989–2018;Maas;Blood Cancer J.,2022

5. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States;Chen;J. Clin. Oncol.,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3